{ "schema_version": "uw.editorial_geo.v1", "representation_profile": "lossless_source_sections", "local_stage_only": true, "catalog_id": "DEP-13-N04", "article_index": "DEP-13-N04", "language": "en", "headline": "Risk after a break: why earlier experience is no guarantee", "description": "Risk after a break: why earlier experience is no guarantee", "short_answer": "“Nothing happened to me before” is an understandable thought when returning to something familiar. Yet a break can change the circumstances: the body's response, treatment, health, access to care or the substance itself may be different. A return to **non-medical opioid use** after extended abstinence or a treatment disruption deserves a specific safety discussion. Past experience cannot calculate the safety of use now. A break alone is not a diagnosis, and resuming prescribed treatment under a clinician's agreed plan is not automatically a “relapse.”\r\n\r\nIf poisoning is suspected, **get medical advice immediately**; if a person cannot be awakened, has a seizure or has severe breathing difficulty, seek **local emergency help now**. The [NHS stresses urgency even when symptoms may be delayed and advises against driving yourself](https://www.nhs.uk/conditions/poisoning/). These steps come before the optional questions below or an ordinary appointment.", "short_answer_source": { "kind": "opening_after_h1", "role": "lead", "start_utf16": 64, "end_utf16": 1026, "sha256_utf8": "74d0030d749ae00c60b2143e54b6e97a16a4af39bab7b94ee0107237220a9667" }, "headline_source": { "role": "h1_heading", "start_utf16": 2, "end_utf16": 60, "sha256_utf8": "e1ced1c8294242ea772e9bb0450b247a3d94ae365b582a86e97ffbd0798566ca" }, "entities": [], "questions": [ { "q": "1. What a break can change", "a": "A break may mean no use of a substance, reduced use, time in treatment, loss of contact with a service, or an interruption to a prescribed medicine. These are different situations. A useful safety conversation asks **what actually stopped**, what happened to the person's health and which support remained available.\r\n\r\nWhen non-medical opioid use resumes, a well-described concern is changed tolerance. A body once accustomed to an exposure may respond differently after time without it. A person cannot reliably infer their current tolerance from a remembered amount, a sense of being “resilient,” or a count of days since last use. One previous episode without harm does not test the next one.\r\n\r\nOther circumstances may have changed too: a new illness, another prescription, sleep, nutrition or a familiar service no longer being nearby. These changes do not prove that overdose is inevitable. They show why the conversation needs to address today's circumstances. A qualified assessment can distinguish risks without blame.", "source_spans": [ { "role": "h2_heading", "start_utf16": 1033, "end_utf16": 1059, "sha256_utf8": "28ea1564990a9a9f7096951f371841c2aa9b78a4b3ee7aed1802055a40582830" }, { "role": "h2_answer", "start_utf16": 1063, "end_utf16": 2091, "sha256_utf8": "58117a2a91eb1aad1993edcaeb3b7919db1d6578657e1db7a0a6c48739f1eff9" } ], "block_ids": [ "p0005", "p0006", "p0007" ], "source_segment_index": 1 }, { "q": "2. Opioids: a specific risk, not a rule for everything", "a": "The [WHO lists resumed opioid use after extended abstinence as an overdose risk factor](https://www.who.int/news-room/fact-sheets/detail/opioid-overdose/), including after detoxification, release from incarceration or treatment cessation. This is about opioids. It does not say that everyone after any short pause will overdose. Opioid overdose is especially dangerous because it can suppress breathing.\r\n\r\nThe [US CDC clinical guideline on prescribed opioids](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm) also identifies people who may return to a previous high opioid exposure after losing tolerance. The guideline is for clinicians treating pain; it gives readers no way to work out an “acceptable” amount. Its relevance here is that a previous regimen and response are not permission to repeat them unaided.\r\n\r\nUncertainty about a substance's contents and the effects of other substances may add risk. Combining opioids with substances that suppress breathing is particularly concerning, but this article does not provide a list for selecting a supposedly better combination. A new exposure or trial return to an old regimen cannot establish safety. If opioids were part of prescribed care, continuing or changing that treatment belongs in a discussion with the prescriber. Having a prescription alone does not establish a substance use disorder.", "source_spans": [ { "role": "h2_heading", "start_utf16": 2098, "end_utf16": 2152, "sha256_utf8": "6d996cf7e722b44d1ca18a3b04021f1635650f0637c1f4da6402741677ce1fb2" }, { "role": "h2_answer", "start_utf16": 2156, "end_utf16": 3514, "sha256_utf8": "7b292d36053500570f5d13bbe2e8a4c3ff339bd18a2298a21539fe948f4c658c" } ], "block_ids": [ "p0009", "p0010", "p0011" ], "source_segment_index": 2 }, { "q": "3. Alcohol, benzodiazepines and other substances raise different questions", "a": "The opioid account of reduced tolerance cannot automatically be applied to alcohol, benzodiazepines or every other substance. They can have their own risks when use or treatment changes, and a specific assessment is needed. In particular, someone who has **drunk heavily for a prolonged period** may face dangerous withdrawal if they stop abruptly. The [NIAAA guide describes this limited situation and the value of medical planning](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help). It does not say that every drinker needs permission to stop.\r\n\r\nWith prescribed benzodiazepines, the question is often the safety of interrupting or changing treatment, rather than “going back to the old dose.” The [FDA warns about possible physical adaptation and serious withdrawal after abrupt stopping following sustained use](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class). Physical adaptation, treatment benefit, side effects and a use disorder are different concepts. A US warning does not become one schedule for every medicine or country.\r\n\r\nNo conclusion about other substances follows solely from this opioid example. When the substance, condition or prescription is unclear, naming it to a professional is more useful than choosing a mechanism of risk alone. None of these distinctions is a home plan to stop, resume or replace a medicine.", "source_spans": [ { "role": "h2_heading", "start_utf16": 3521, "end_utf16": 3595, "sha256_utf8": "0440bacbc92c6a4ee4e042412a03a7ad9d36648f854e75aa3d3550d762bd87dd" }, { "role": "h2_answer", "start_utf16": 3599, "end_utf16": 5091, "sha256_utf8": "b5d27f6b73de348854b20ee3c64af40a1d81065ad6022347800f996cf0073d3e" } ], "block_ids": [ "p0013", "p0014", "p0015" ], "source_segment_index": 3 }, { "q": "4. When medical care has been interrupted", "a": "A clinician-agreed pause can be part of ordinary care. A different situation arises when a prescription or service connection stops because of a waiting list, move, cost, illness or another obstacle. The person does not have to prove “willpower” before saying that contact has been lost. Tell the service what happened and establish a safe next contact.\r\n\r\nIn its [overview of guidance on opioid agonist maintenance treatment for people with opioid dependence](https://www.who.int/publications/i/item/B09543), the WHO stresses the value of maintaining care through disruption. The guidance chiefly addresses systems and professionals; it does not promise that a service exists in every locality. If an interruption has already happened, the useful step is to restore qualified contact, not devise a previous regimen independently.\r\n\r\nFor any prescribed medicine, ask the prescriber or another accessible healthcare professional what to do after a missed period and which health changes they need to know. The [FDA advises discussing use that differs from directions with a healthcare professional](https://www.fda.gov/drugs/information-consumers-and-patients-drugs/think-it-through-managing-benefits-and-risks-medicines). Do not guess a regimen from an old package, someone else's experience or this article. Care for a use disorder, pain treatment and withdrawal management may have different goals and providers.", "source_spans": [ { "role": "h2_heading", "start_utf16": 5098, "end_utf16": 5139, "sha256_utf8": "b61b65999f161198c100cebacd6b60b73c844ee61f39bc2a5fa3aa7f95456ad1" }, { "role": "h2_answer", "start_utf16": 5143, "end_utf16": 6557, "sha256_utf8": "9b8fef57221772abee6e270d962aa04ca9ff68942ce5d53a9348422b739aacfa" } ], "block_ids": [ "p0017", "p0018", "p0019" ], "source_segment_index": 4 }, { "q": "5. Suspected overdose: help comes first", "a": "An opioid overdose may involve difficulty waking someone and slow or troubled breathing. Do not wait for every sign to appear: suspected poisoning needs immediate medical advice, while unconsciousness, a seizure or severe breathing difficulty needs local emergency services. A relative need not identify the exact substance or establish a diagnosis first.\r\n\r\nThe [CDC describes naloxone for suspected opioid overdose alongside a call for emergency help](https://www.cdc.gov/stop-overdose/response/). Naloxone acts in the opioid context; local access and training vary. This article gives no dose or administration instructions. If a person looks better after naloxone, **emergency medical care and observation are still needed**: apparent improvement does not prove the danger has ended. Naloxone does not replace care for other kinds of poisoning.\r\n\r\nAfter the acute episode, a qualified service can help discuss what was known about the break and how to maintain contact. That conversation matters even if the person is not ready to promise complete abstinence. Emergency care must not wait for a completed map, a family conversation or a routine appointment.", "source_spans": [ { "role": "h2_heading", "start_utf16": 6564, "end_utf16": 6603, "sha256_utf8": "5c54854af3c71cb769a1aa78408c4fa843d676cd4e5590aafc06e1ceea7b9a73" }, { "role": "h2_answer", "start_utf16": 6607, "end_utf16": 7768, "sha256_utf8": "f6418c5ecfc63ead25914f4f90d091d4be9fb94bef2377b9145879f0793a2d54" } ], "block_ids": [ "p0021", "p0022", "p0023" ], "source_segment_index": 5 }, { "q": "6. A separate safety conversation", "a": "A first conversation can be short: “My situation changed after a break. I want to discuss the risks and where to turn now.” Share only what is already known: the substance or medicine involved, what was interrupted, new symptoms, changes to prescriptions and whether the treating service is still in contact. If a detail is unknown, say so. There is no need for a new “test,” proof through use or information that would be unsafe to obtain.\r\n\r\nAsk who can actually assess the situation, how soon contact is possible and what happens if the needed service is unavailable. Age, language, cost, waiting and privacy conditions vary locally. Booking, receiving a call back and actually getting help are different stages. If a referral fails, tell the service and ask for a concrete next option.\r\n\r\nAn adult decides which details to share with close people; a clinician needs information relevant to safety. Ask a particular service about records and information sharing, rather than assuming absolute confidentiality or none at all. Returning to a conversation after a break is not an admission of “failure.”", "source_spans": [ { "role": "h2_heading", "start_utf16": 7775, "end_utf16": 7808, "sha256_utf8": "08243d237ecdc0e08c9c18dd52bdb72fc1a7329c2f1d9fa1b66e360675fe021c" }, { "role": "h2_answer", "start_utf16": 7812, "end_utf16": 8915, "sha256_utf8": "c7865bc051e9baa57c7d04e7526789c0715dd5fa479f7890d112ae5b08df046b" } ], "block_ids": [ "p0025", "p0026", "p0027" ], "source_segment_index": 6 }, { "q": "7. Support after the first contact", "a": "Reducing risk involves more than an overdose warning. Real benefits can include assessment of changed circumstances, restored contact with a service, review of prescribed care, help with another health condition and a clear continuation after the first visit. Options depend on the substance, condition, the person's goals and the local system. A professional can distinguish an urgent need from a longer-term care plan.\r\n\r\nIf an appointment has been booked, clarify who is responsible for the next step and what to do if health worsens before it. If the appointment did not happen, help can still be sought. A person does not need a final meaning in life, perfect motivation or ideal surroundings before care. Work, relationships, family responsibilities and personal goals can matter in the plan, but they do not replace assessment of a dangerous condition.\r\n\r\nA genuinely better period of control or a helpful treatment need not be dismissed. Neither guarantees that today's conditions are unchanged. Discussing what has already changed is safer than trying to prove former “resilience” through renewed use.", "source_spans": [ { "role": "h2_heading", "start_utf16": 8922, "end_utf16": 8956, "sha256_utf8": "6a9820682b16f35afe77cfba1f10160adaa165c5a4a3aa6dbc027b011ac12f1c" }, { "role": "h2_answer", "start_utf16": 8960, "end_utf16": 10070, "sha256_utf8": "459d07498e4faf92e407bfdc095b2acc01f08ff7a26900002f517411b66e767d" } ], "block_ids": [ "p0029", "p0030", "p0031" ], "source_segment_index": 7 }, { "q": "8. Close people, consent and independent safety", "a": "A close person may help find a service, arrange transport or accompany a visit if the adult wants that and the helper agrees. Kinship does not give someone permission to secretly take medicines, money or a phone, set up surveillance or decide another adult's treatment. A helper may protect their own funds and boundaries without becoming a round-the-clock emergency service.\r\n\r\nChildren must not be asked to check use, keep or dispense medicines, monitor an adult's breathing or carry messages between adults and services. Suitable adults and local services arrange a child's safe care. With violence, threats or coercion, the person at risk needs separate protection; a joint conversation is not a precondition for safety.\r\n\r\nIt is possible to start without every relative's agreement, for example by asking an accessible service about its first contact and conditions. If help is urgent, seek it now. Support and closeness may help, but love does not oblige someone to accept harm and is not an entry ticket to treatment.", "source_spans": [ { "role": "h2_heading", "start_utf16": 10077, "end_utf16": 10124, "sha256_utf8": "6a12ed17c39f574c5deb952e1a416f9d4b33c1a5bd132df8c34dc458ea64460e" }, { "role": "h2_answer", "start_utf16": 10128, "end_utf16": 11152, "sha256_utf8": "c063cf2b8ff9343ae4f575282d544267122aef5f0c19cebe79c8f563cf01c9f5" } ], "block_ids": [ "p0033", "p0034", "p0035" ], "source_segment_index": 8 }, { "q": "Appendix: five optional anchors", "a": "These original questions concern only what is already known. They are not a diagnostic scale, use instructions or a condition of care. Skip any item; do not return to a substance, change a medicine or perform a test to answer it.\r\n\r\n1. **Break.** What actually stopped or changed: use, prescribed treatment or contact with a service?\r\n2. **Condition.** Which changes already noticed in health, sleep, breathing or how I feel should a professional know?\r\n3. **Prescriptions.** Which medicines or earlier instructions are already known, and with whom can I discuss whether they still apply?\r\n4. **Contact.** Which service or professional is available for an initial conversation, and what is known about cost, language, waiting and privacy?\r\n5. **Continuation.** How will I know help was actually received, and whom can I tell if contact breaks again?", "source_spans": [ { "role": "h2_heading", "start_utf16": 11159, "end_utf16": 11190, "sha256_utf8": "a956852ee0a0fcfc88b32f56bb15eafd3a2d916d26f912a5a88b6b3c38749a94" }, { "role": "h2_answer", "start_utf16": 11194, "end_utf16": 12043, "sha256_utf8": "27ec9f907a0aa375934c01fe562758e1e67c73d87ab97dd5021203ada07b4926" } ], "block_ids": [ "p0037", "p0038" ], "source_segment_index": 9 }, { "q": "Sources and limits of application", "a": "Content checked 14 October 2026. These sources have different genres and scopes. Loss of tolerance is discussed primarily for opioids; US rules and services are not universal conditions for readers elsewhere.\r\n\r\n- WHO, [Opioid overdose](https://www.who.int/news-room/fact-sheets/detail/opioid-overdose/), 29 August 2025, fact sheet. Opioid risk factors, naloxone and subsequent observation; not an individual assessment or a rule for every substance.\r\n- CDC, [Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm), 2022 US clinician guideline. Risk after lost tolerance within opioid prescribing; not a safe-amount calculation for readers.\r\n- WHO, [Opioid agonist maintenance treatment as an essential health service](https://www.who.int/publications/i/item/B09543), 13 October 2025, technical-document overview. Continuity of care for opioid dependence; local service availability varies.\r\n- NHS, [Poisoning](https://www.nhs.uk/conditions/poisoning/), page reviewed 12 June 2025, UK medical information. Urgency for suspected poisoning; emergency numbers and access vary by country.\r\n- CDC, [What to Do If You Think Someone Is Overdosing](https://www.cdc.gov/stop-overdose/response/), 2 April 2024, US public information. Naloxone and emergency contact in suspected opioid overdose; local access is not assured.\r\n- FDA, [Benzodiazepine boxed-warning safety communication](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class), 23 September 2020, US regulator communication. Physical adaptation and withdrawal with benzodiazepines; not an individual treatment schedule.\r\n- NIAAA, [Treatment for Alcohol Problems: Finding and Getting Help](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help), no explicit page date, US alcohol-care guide. Withdrawal after prolonged heavy drinking and continued support; not a rule for every drinker.\r\n- FDA, [Think It Through: Managing the Benefits and Risks of Medicines](https://www.fda.gov/drugs/information-consumers-and-patients-drugs/think-it-through-managing-benefits-and-risks-medicines), no explicit page date, general US patient guidance. Discussing prescription changes with a professional, not instructions for restarting.", "source_spans": [ { "role": "h2_heading", "start_utf16": 12050, "end_utf16": 12083, "sha256_utf8": "5eb1909264375549557460b1ab6bea7d0384a644a05cd035c8fc6bb8f7ce6425" }, { "role": "h2_answer", "start_utf16": 12087, "end_utf16": 14484, "sha256_utf8": "fa613bb0d1c4d822e4189c6b2071d6965324aaa1f9a51a0505c999cc91131344" } ], "block_ids": [ "p0040", "p0041" ], "source_segment_index": 10 }, { "q": "Tags", "a": "addiction, break, safety, opioids, tolerance, overdose, naloxone, alcohol, benzodiazepines, treatment, support, recovery", "source_spans": [ { "role": "h2_heading", "start_utf16": 14491, "end_utf16": 14495, "sha256_utf8": "1331275bc537b4c2bf1e46f7275677967515342e30b572e6852fa6f51b831fe8" }, { "role": "h2_answer", "start_utf16": 14499, "end_utf16": 14619, "sha256_utf8": "d809edaa8322414d007787d7bdf097936f66b415f86685be7f26a34f20591c2a" } ], "block_ids": [ "p0043" ], "source_segment_index": 11 }, { "q": "About the authors", "a": "Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue and contemporary spiritual discipline. Instagram: @andrey.zarinsh.\r\n\r\nMaria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.", "source_spans": [ { "role": "h2_heading", "start_utf16": 14626, "end_utf16": 14643, "sha256_utf8": "e120452a2b9952200310f55df00e52d0bbd068d32bba8a322511ed65e3d4967d" }, { "role": "h2_answer", "start_utf16": 14647, "end_utf16": 15085, "sha256_utf8": "8d1b4a5346c9f002c1138ddb338d6ff44f5f2df593c29b285e318fa19b05735d" } ], "block_ids": [ "p0045", "p0046" ], "source_segment_index": 12 } ], "claims": [], "claims_policy": "no_reclassified_claims", "sources": [ { "id": "src_10790fb1fab48f9a", "title": "Poisoning", "url": "https://www.nhs.uk/conditions/poisoning/", "source_spans": [ { "role": "markdown_link", "start_utf16": 809, "end_utf16": 944, "sha256_utf8": "7aeb10f502f74dec66464a00f74bbc2bc4a884ce375dc31e5726a9b1f1cc3425" }, { "role": "markdown_link", "start_utf16": 13068, "end_utf16": 13121, "sha256_utf8": "3c8cfe2e89df1bd35f78dd41a2c472a438b265717bc6d7a2b906acc0e10d8dff" } ], "read_scope": "- NHS, [Poisoning](https://www.nhs.uk/conditions/poisoning/), page reviewed 12 June 2025, UK medical information. Urgency for suspected poisoning; emergency numbers and access vary by country.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13061, "end_utf16": 13253, "sha256_utf8": "320a149492e218fb467818baffd97dce221ae6f47f01a5f3f040c8f846be6f6d" }, "shared_entry_urls": [] }, { "id": "src_653aa252360a65a9", "title": "Opioid overdose", "url": "https://www.who.int/news-room/fact-sheets/detail/opioid-overdose/", "source_spans": [ { "role": "markdown_link", "start_utf16": 2160, "end_utf16": 2310, "sha256_utf8": "ecaf52ae54a47ae593ff71fa17fb8c9170d8e37ec96968b7a2b8adacebda347c" }, { "role": "markdown_link", "start_utf16": 12306, "end_utf16": 12390, "sha256_utf8": "3d6d29f92b2293c9c13f159bded4bb6306055a5e29ebf2a89a702239e4627a14" } ], "read_scope": "- WHO, [Opioid overdose](https://www.who.int/news-room/fact-sheets/detail/opioid-overdose/), 29 August 2025, fact sheet. Opioid risk factors, naloxone and subsequent observation; not an individual assessment or a rule for every substance.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12299, "end_utf16": 12537, "sha256_utf8": "6f273c829be0772540bb849b24b08cee7f30a25aeec2e59d2091ec70f8c1a6ee" }, "shared_entry_urls": [] }, { "id": "src_ede712eaefe50ff2", "title": "Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022", "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm", "source_spans": [ { "role": "markdown_link", "start_utf16": 2567, "end_utf16": 2669, "sha256_utf8": "580bfbf0a3beaf0e47bfc35decfe349635e81f8c65dbd3ccab1868d0d3bb8d89" }, { "role": "markdown_link", "start_utf16": 12546, "end_utf16": 12683, "sha256_utf8": "0f6eb501cc81629812c88ee384d1aa2adbf5e19418b71f0db68763d947cf06a3" } ], "read_scope": "- CDC, [Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm), 2022 US clinician guideline. Risk after lost tolerance within opioid prescribing; not a safe-amount calculation for readers.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12539, "end_utf16": 12809, "sha256_utf8": "9e2ccb5569d48477b9a683a8da391052c0a1d94400970a6e5a9f1d3b00626b82" }, "shared_entry_urls": [] }, { "id": "src_6dc3b3a2dfcc6f51", "title": "Treatment for Alcohol Problems: Finding and Getting Help", "url": "https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help", "source_spans": [ { "role": "markdown_link", "start_utf16": 3952, "end_utf16": 4150, "sha256_utf8": "4aa4e980d6027ecb3240c5de57c562c9302e52be537e9d1ec2ab24078f6e3a91" }, { "role": "markdown_link", "start_utf16": 13831, "end_utf16": 14007, "sha256_utf8": "64bea7c2da074954b3ee720e272eede809f80d5614f7b3d065b74667fafc88b8" } ], "read_scope": "- NIAAA, [Treatment for Alcohol Problems: Finding and Getting Help](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help), no explicit page date, US alcohol-care guide. Withdrawal after prolonged heavy drinking and continued support; not a rule for every drinker.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13822, "end_utf16": 14149, "sha256_utf8": "11ed0051c63443a6df3f168482fa35e34492c29ff29a04c2c0ebae525cf8646b" }, "shared_entry_urls": [] }, { "id": "src_463998ce56ffef4c", "title": "Benzodiazepine boxed-warning safety communication", "url": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class", "source_spans": [ { "role": "markdown_link", "start_utf16": 4367, "end_utf16": 4617, "sha256_utf8": "d0d3e2c6502436963020fcb2b558f8e441565cde3f42288368fb35019c114e75" }, { "role": "markdown_link", "start_utf16": 13491, "end_utf16": 13677, "sha256_utf8": "ad17e2684cb7dc19d8ae4de4972553bb1c46b8f915a29a73783690c6896fec90" } ], "read_scope": "- FDA, [Benzodiazepine boxed-warning safety communication](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class), 23 September 2020, US regulator communication. Physical adaptation and withdrawal with benzodiazepines; not an individual treatment schedule.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13484, "end_utf16": 13820, "sha256_utf8": "0e05787d665dba1e2df7383be5865ea12b4bf7fb1328dcd13337c0f7b57b8db4" }, "shared_entry_urls": [] }, { "id": "src_71784f22f96e7b44", "title": "Opioid agonist maintenance treatment as an essential health service", "url": "https://www.who.int/publications/i/item/B09543", "source_spans": [ { "role": "markdown_link", "start_utf16": 5507, "end_utf16": 5651, "sha256_utf8": "570a0a73f544f757599e47bd4b116d94d9ec514b50dd93bc677a4f32af730a85" }, { "role": "markdown_link", "start_utf16": 12818, "end_utf16": 12935, "sha256_utf8": "f5bcabd8c01e0424a0e6b1000509e59221def7ebb41e9f3fe67e796e26032fca" } ], "read_scope": "- WHO, [Opioid agonist maintenance treatment as an essential health service](https://www.who.int/publications/i/item/B09543), 13 October 2025, technical-document overview. Continuity of care for opioid dependence; local service availability varies.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 12811, "end_utf16": 13059, "sha256_utf8": "906907da6ceb43407f5f6d6215a39242c630ccd0c274732410f7927c2d0a49b0" }, "shared_entry_urls": [] }, { "id": "src_ce9f13a2bcec6c3b", "title": "Think It Through: Managing the Benefits and Risks of Medicines", "url": "https://www.fda.gov/drugs/information-consumers-and-patients-drugs/think-it-through-managing-benefits-and-risks-medicines", "source_spans": [ { "role": "markdown_link", "start_utf16": 6152, "end_utf16": 6363, "sha256_utf8": "74db17c1096165a3730ee865449648b19a4cf270436809f2ebcbba90eda02e1e" }, { "role": "markdown_link", "start_utf16": 14158, "end_utf16": 14345, "sha256_utf8": "cd4757eccf97981ce3381e8a7234fc22dd7939423d085cf2cba9e6305d40f6c3" } ], "read_scope": "- FDA, [Think It Through: Managing the Benefits and Risks of Medicines](https://www.fda.gov/drugs/information-consumers-and-patients-drugs/think-it-through-managing-benefits-and-risks-medicines), no explicit page date, general US patient guidance. Discussing prescription changes with a professional, not instructions for restarting.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 14151, "end_utf16": 14484, "sha256_utf8": "b292c46652fc165169f39db236c3f6096da41bb5dd0c1732603dc5416dbeee29" }, "shared_entry_urls": [] }, { "id": "src_4fb9868c240da1f3", "title": "What to Do If You Think Someone Is Overdosing", "url": "https://www.cdc.gov/stop-overdose/response/", "source_spans": [ { "role": "markdown_link", "start_utf16": 6970, "end_utf16": 7105, "sha256_utf8": "d124b41312de1be84d3d8a82e724242870ae3bfbf074113c6f7535fdd445781e" }, { "role": "markdown_link", "start_utf16": 13262, "end_utf16": 13354, "sha256_utf8": "3af2b1f889945f9736f5ed16532a6bfd88441a31e9a6c298c38d57671222d949" } ], "read_scope": "- CDC, [What to Do If You Think Someone Is Overdosing](https://www.cdc.gov/stop-overdose/response/), 2 April 2024, US public information. Naloxone and emergency contact in suspected opioid overdose; local access is not assured.", "read_scope_kind": "verbatim_bibliography_entry", "read_scope_span": { "role": "bibliography_entry", "start_utf16": 13255, "end_utf16": 13482, "sha256_utf8": "ded4bcbcdfabc4c1b76e7f220bb4b15432da39f30f93e98ea7768fc7b02bb518" }, "shared_entry_urls": [] } ], "retrieval_limits": [ "This local GEO representation applies only to the specified source article version and its SHA-256.", "Qualifications, sources and attributions remain in the full sections and byte-identical Markdown copy.", "No new source research was conducted in this GEO stage." ], "master_sha256": "51fbfaf2434e7e033f44d29377f44025e63dea2fcef8b0e0b24a045ed1b82d52", "provenance": { "raw_reader_sha256": "51fbfaf2434e7e033f44d29377f44025e63dea2fcef8b0e0b24a045ed1b82d52", "ru_master_sha256": "7298b87a042c84bee3b990594edddf9f4a6f253c7b95b112204fa9e95087ec46", "reader_path": "outputs/uw-addictions-corpus-20261013/articles/DEP-13-N04/ARTICLE_EN.md", "review_pointer": "outputs/uw-addictions-corpus-20261013/articles/DEP-13-N04/INDEPENDENT_REVIEW.json", "review_sha256": "89c4bee975d1813f2a400dd2fd14ecd64c07e582bc483ce6ec24c42a9832d1ff", "clean_md_relative_filename": "GEO.en.md", "body_length_utf16": 15087, "source_segments": [ { "kind": "opening", "index": 0, "heading": null, "start_utf16": 0, "end_utf16": 1030, "sha256_utf8_raw_slice": "62d1264dccc73c6dd3748038b16b03c64ae274cde03641ae405568920cac13c8" }, { "kind": "h2_section", "index": 1, "heading": "1. What a break can change", "start_utf16": 1030, "end_utf16": 2095, "sha256_utf8_raw_slice": "1dbdf95d0e1333c5037e5c01f28fa072a806c51a12808a3634d4dcad69da0fca" }, { "kind": "h2_section", "index": 2, "heading": "2. Opioids: a specific risk, not a rule for everything", "start_utf16": 2095, "end_utf16": 3518, "sha256_utf8_raw_slice": "b138112358f4448672ff0ddf7bd4d3064f7334ebeeafab0546a8711d2e722183" }, { "kind": "h2_section", "index": 3, "heading": "3. Alcohol, benzodiazepines and other substances raise different questions", "start_utf16": 3518, "end_utf16": 5095, "sha256_utf8_raw_slice": "96c2a1c8e2538d98326f19bf1f5cb7bb6d8896a85613c6a88bf2208b605cb3e4" }, { "kind": "h2_section", "index": 4, "heading": "4. When medical care has been interrupted", "start_utf16": 5095, "end_utf16": 6561, "sha256_utf8_raw_slice": "c3fd8ed833af1938af209ffad4a48c9a8c28cebc27e8e6845d96274b78177e90" }, { "kind": "h2_section", "index": 5, "heading": "5. Suspected overdose: help comes first", "start_utf16": 6561, "end_utf16": 7772, "sha256_utf8_raw_slice": "e68a38b774ac6bf941088a502de521f94798ccec416e1e76b8364e8a0589fb0f" }, { "kind": "h2_section", "index": 6, "heading": "6. A separate safety conversation", "start_utf16": 7772, "end_utf16": 8919, "sha256_utf8_raw_slice": "46741c66a19e49b14f4495ba9dc80b40a6a99bd96700773edaac6fc86ff8c02f" }, { "kind": "h2_section", "index": 7, "heading": "7. Support after the first contact", "start_utf16": 8919, "end_utf16": 10074, "sha256_utf8_raw_slice": "cc6814082be493540f1f299c8c57af220fd30832cdf896cfbc89a67f1a39c43f" }, { "kind": "h2_section", "index": 8, "heading": "8. Close people, consent and independent safety", "start_utf16": 10074, "end_utf16": 11156, "sha256_utf8_raw_slice": "f5bf80bedb5fd8136c5e1d77e9285d47ea14259140c7a1f5540a682d8bde5b9a" }, { "kind": "h2_section", "index": 9, "heading": "Appendix: five optional anchors", "start_utf16": 11156, "end_utf16": 12047, "sha256_utf8_raw_slice": "92fecef87e39d89c8eddf5cda653e95e95512196ee7e3409e7aca51dc21f2702" }, { "kind": "h2_section", "index": 10, "heading": "Sources and limits of application", "start_utf16": 12047, "end_utf16": 14488, "sha256_utf8_raw_slice": "4c95d73042823bb91ca1a0aec46b95b65bb71ca2da41ffb004969c5488cbab28" }, { "kind": "h2_section", "index": 11, "heading": "Tags", "start_utf16": 14488, "end_utf16": 14623, "sha256_utf8_raw_slice": "a343f9a2c33cb8fe10f159011b4c27b532ea4eb2e710b6e7a663e6f0574b3fc2" }, { "kind": "h2_section", "index": 12, "heading": "About the authors", "start_utf16": 14623, "end_utf16": 15087, "sha256_utf8_raw_slice": "23e131522dee408b57dfc256d27af894c2621c6e514f5fb39b9289dfad1dae6b" } ], "common_blocks_module_sha256": "6cf638661a819f960c39d08058bf6d0d0696e8b816f677d95b389f5f1d11e4d2" } }